Experience

Stibbe represents Mylan in successful takeover defence against Teva’s hostile bid and the EU Merger Control proceedings related to the Perrigo offer

Stibbe represents Mylan in successful takeover defence against Teva’s hostile bid and the EU Merger Control proceedings related to the Perrigo offer

Stibbe represents Mylan in successful takeover defence against Teva’s hostile bid and the EU Merger Control proceedings related to the Perrigo offer

30.07.2015 NL law

On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition law-related matters.

On April 8, 2015, Mylan announced that it has made a proposal to acquire Perrigo Company plc in a cash‑and‑stock transaction worth over 25 billion USD. Stibbe represented Mylan in the EU Merger Control proceedings before the European Commission. On 29 July 2015, the European Commission unconditionally approved the transaction under the EU Merger Regulation.

The Stibbe team was led by partners Fons Leijten, Jeroen Kortmann and Rein Wesseling and includes Damien Berkhout and Olivier Schotel on litigation matters; Floris ten Have, Jan Truijens Martinez, Jordy de Meij, Evangelia Demertzi, Dirk de Graeff and Vincent Lampers on EU competition law. On the Teva matter Stibbe worked alongside Cravath Swaine & Moore LLP; NautaDutilh’s litigation team; Arthur Cox; Wilson Sonsini Goodrich & Rosati and Meitar Liquornik Geva Leshem Tal. On the antitrust aspects of the Perrigo matter Stibbe worked alongside Cravath Swaine & Moore LLP.

Team

Related experience

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring